ATBPF News and Press, Antibe Therapeutics From 04/11/23

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formu...

Antibe Therapeutics press release ( OTCQX:ATBPF ): Q3 GAAP EPS of -$0.08. As of December 31, 2022, the Company had available cash balance and term deposits totaling $42.4 million, compared to $54.8 million as at March 31, 2022. This provides the Company with over two years of runway, ...

- Recent animal data on otenaproxesul's new formulation confirm rapid drug uptake and potential for effective pain management - Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months - Ended quarter with $42.4 million in cash and equivalents, provid...

Antibe Therapeutics press release ( OTCQX:ATBPF ): Q2 GAAP EPS of -$0.12 misses by $0.03 . As of September 30, 2022, the Company had an available cash balance and term deposits totaling $45.4 million, compared to $54.8 million as at March 31, 2022. This provides the Co...

- Progress includes otenaproxesul’s new formulation, strengthened IP and robust third-party sales projections - Sale of Citagenix subsidiary provides non-dilutive funding - Ended quarter with $45.4 million in cash and equivalents, providing over two ye...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (&#...

- Patent application filed for improved formulation; strengthens IP protection to 2042 - Anticipated benefits include faster onset of action, lower doses - Phase II molar study no longer required; Phase II bunionectomy study on track for H1 2023 A...

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”...

- Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target infl...

Antibe Therapeutics Inc. press release ( OTCQX:ATBPF ): Q1 GAAP EPS of -$0.10 misses by $0.02 . The Company had an available cash balance and term deposits totaling $50.2 million. For further details see: Antibe Therapeutics Inc. GAAP EPS of -$0.10 misses by $0.0...